SPINAL MAST CELL TUMORS IN DOGS: IMAGING FEATURES AND CLINICAL OUTCOME OF FOUR CASES

2016 ◽  
Vol 58 (1) ◽  
pp. 44-52 ◽  
Author(s):  
Trevor W. Moore ◽  
R. Timothy Bentley ◽  
Sarah A. Moore ◽  
Michele Provencher ◽  
Emma E. Warry ◽  
...  
Keyword(s):  
Mast Cell ◽  
Clinical Outcome ◽  
Imaging Features ◽  
Mast Cell Tumors

scholarly journals Stereology in Grading and Prognosis of Canine Cutaneous Mast Cell Tumors

2021 ◽  
pp. 030098582098513
Author(s):  
Mafalda Casanova ◽  
Sandra Branco ◽  
Inês Berenguer Veiga ◽  
André Barros ◽  
Pedro Faísca
Keyword(s):  
Mast Cell ◽  
Clinical Outcome ◽  
Prognostic Value ◽  
Histological Grade ◽  
Intraobserver Variability ◽  
Low Grade ◽  
High Grade ◽  
Mast Cell Tumors ◽  
Cutaneous Mast Cell ◽  
Grade Iii

Canine cutaneous mast cell tumors (ccMCTs) are currently graded according to Patnaik and Kiupel grading schemes. The qualitative and semiquantitative parameters applied in these schemes may lead to inter- and intraobserver variability. This study investigates the prognostic value of volume-weighted mean nuclear volume ([Formula: see text]), a stereological estimation that provides information about nuclear size and its variability. [Formula: see text] of 55 ccMCTs was estimated using the “point-sampled intercept” method and compared with histological grade and clinical outcome. The clinical history of dogs treated with surgical excision alone was available for 30 ccMCTs. Statistical differences in [Formula: see text] were found between grade II ([Formula: see text]= 115 ± 29 µm3) and grade III ccMCTs ([Formula: see text]= 197 ± 63 µm3), as well as between low-grade ([Formula: see text]= 113 ± 28 µm3) and high-grade ccMCTs ([Formula: see text]= 184 ± 63 µm3). An optimal cutoff value of [Formula: see text] ≥ 150 µm3 and [Formula: see text] ≥ 140 µm3 was determined for grade III and high-grade ccMCTs, respectively. In terms of prognosis, [Formula: see text] was not able to predict the clinical outcome in 42% of the cases; however, cases with [Formula: see text]<125 µm3 had a favorable outcome. These results indicate that, despite having limited prognostic value when used as a solitary parameter, [Formula: see text] is highly reproducible and is associated with histological grade as well as with benign behavior.

Chirurgie subkutaner Mastzelltumoren beim Hund: Prognosefaktoren und Outcome

2021 ◽  
Vol 49 (03) ◽  
pp. 228-228
Author(s):  
Daniela Simon Betz
Keyword(s):  
Mast Cell ◽  
Clinical Outcome ◽  
Proliferating Cell Nuclear Antigen ◽  
Prognostische Faktoren ◽  
Microvascular Density ◽  
Nuclear Antigen ◽  
Prognostic Indicators ◽  
Ki 67 ◽  
Mast Cell Tumors ◽  
Proliferating Cell

Gill V, Leibman N, Monette S et al. Prognostic Indicators and Clinical Outcome in Dogs with Subcutaneous Mast Cell Tumors. J Am Anim Hosp Assoc 2020; 56 (4): 215–225 Mastzelltumoren (MZT) sind häufige kutane Neoplasien beim Hund, für die verschiedene prognostische Faktoren beschrieben wurden. Zu diesen zählen der histologische Grad nach Patnaik (3 Grade) oder Kiupel (2 Grade) sowie einige Marker zellulärer Differenzierung wie AgNORs (agyrophylic nuclear organizer regions), Ki-67 oder PCNA (proliferating cell nuclear antigen). Weitere prognostisch aussagekräftige Parameter sind der c-Kit-Mutationsstatus, die mikrovaskuläre Dichte (microvascular density, MVD) und der mitotische Index (MI). Ziel der Studie war, den klinischen Verlauf nach operativer Entfernung subkutaner MZT beim Hund auszuwerten und die Wertigkeit der verschiedenen Prognosefaktoren zu validieren.

scholarly journals Genomic copy number variation associated with clinical outcome in canine cutaneous mast cell tumors

2017 ◽  
Vol 111 ◽  
pp. 26-30 ◽  
Author(s):  
Paulo C Jark ◽  
Deborah B.P. Mundin ◽  
Marcio de Carvalho ◽  
Raquel B. Ferioli ◽  
Letícia A Anai ◽  
...  
Keyword(s):  
Mast Cell ◽  
Clinical Outcome ◽  
Copy Number Variation ◽  
Copy Number ◽  
Genomic Copy Number ◽  
Mast Cell Tumors ◽  
Genomic Copy ◽  
Number Variation ◽  
Cutaneous Mast Cell ◽  
Genomic Copy Number Variation

Clinical outcome of dogs with grade-II mast cell tumors treated with surgery alone: 55 cases (1996-1999)

2001 ◽  
Vol 218 (7) ◽  
pp. 1120-1123 ◽  
Author(s):  
Bernard Seguin ◽  
Nicole F. Leibman ◽  
Victoria S. Bregazzi ◽  
Gregory K. Ogilvie ◽  
Barbara E. Powers ◽  
...  
Keyword(s):  
Mast Cell ◽  
Clinical Outcome ◽  
Mast Cell Tumors ◽  
Grade Ii

Prognostic Indicators and Clinical Outcome in Dogs with Subcutaneous Mast Cell Tumors Treated with Surgery Alone: 43 Cases

2020 ◽  
Vol 56 (4) ◽  
pp. 215-225 ◽  
Author(s):  
Virginia Gill ◽  
Nicole Leibman ◽  
Sebastien Monette ◽  
Diane M. Craft ◽  
Philip J. Bergman
Keyword(s):  
Mast Cell ◽  
Clinical Outcome ◽  
Proliferating Cell Nuclear Antigen ◽  
Nuclear Antigen ◽  
Grading System ◽  
Nucleolar Organizer Regions ◽  
Low Grade ◽  
Mast Cell Tumors ◽  
Proliferating Cell

ABSTRACT The purpose of this study was to determine if clinical findings, histologic grade, or other histologic features were associated with clinical outcome in dogs with subcutaneous mast cell tumors (MCTs). Medical records of 43 client-owned dogs were retrospectively reviewed, and follow-up information was gathered via phone or follow-up examination. Progression-free survival (PFS), disease-free interval (DFI), and overall survival were calculated. Forty-two and twenty-two dogs, respectively, had grade 2 (Patnaik grading system) or low-grade tumors (two-tier grading system). Median PFS was 1474 days. Median DFI was not reached at &gt;1968 days. Overall median survival time was not reached at &gt;1968 days. In univariate analysis, argyrophilic nucleolar organizer regions (AgNORs), proliferating cell nuclear antigen, and mitotic index were negatively prognostic for PFS whereas Ki-67, proliferating cell nuclear antigen, and microvessel density were negatively prognostic for DFI. In multivariate analysis, AgNORs remained negatively prognostic for PFS. Results suggest that proliferation indices, especially AgNORs, may be useful in predicting the rare poor outcomes in dogs with subcutaneous MCTs. The vast majority of subcutaneous MCTs appear to be low or intermediate grade with excellent outcomes from good local tumor control.

Clinicopathological and Imaging Features Predictive of Clinical Outcome in Metaplastic Breast Cancer

2020 ◽  
Vol 16 (6) ◽  
pp. 729-738
Author(s):  
Ga Young Yoon ◽  
Joo Hee Cha ◽  
Hak Hee Kim ◽  
Hee Jung Shin ◽  
Eun Young Chae ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Outcome ◽  
Clinical Outcomes ◽  
Tumor Size ◽  
Multivariable Analysis ◽  
Disease Free Survival ◽  
Imaging Features ◽  
Peritumoral Edema ◽  
Imaging Findings ◽  
Metaplastic Breast Cancer

Background: Metaplastic breast cancer (MC) is a rare disease, thus it is difficult to study its clinical outcomes. Objective: To investigate whether any clinicopathological or imaging features were associated with clinical outcome in MC. Methods: We retrospectively evaluated the clinicopathological and imaging findings, and the clinical outcomes of seventy-two pathologically confirmed MCs. We then compared these parameters between triple-negative (TNMC) and non-TNMCs (NTNMC). Results: Oval or round shape, and not-circumscribed margin were the most common findings on mammography, ultrasound (US), and magnetic resonance imaging (MRI). It was mostly a mass without calcification on mammography, and revealed complex or hypoechoic echotexture, and posterior acoustic enhancement on US, and rim enhancement, wash-out kinetics, peritumoral edema, and intratumoral necrosis on MRI. Of all 72, 64 were TNMCs, and eight were NTNMCs. Clinicopathological and imaging findings were similar between the two groups, except that MRI showed peritumoral edema more frequently in TNMCs than NTNMCs (p=0.045). There were 21 recurrences and 13 deaths. Multivariable analysis showed that larger tumor size and co-existing DCIS were significantly predictive of Disease free survival (DFS), and larger tumor size and neoadjuvant chemotherapy were significantly predictive of overall survival (OS). Conclusion: MC showed characteristic imaging findings, and some variables associated with survival outcome may help to predict prognosis.

Immunohistochemical Expression of Vascular Endothelial Growth Factor as a Prognostic Marker for Canine Mast Cell Tumors

2021 ◽  
Vol 42 ◽  
pp. 100506
Author(s):  
Samanta Rios Melo ◽  
Eric Vieira Januário ◽  
Erika Zanuto ◽  
Bruna de Castro Miranda ◽  
Thais Rodrigues Macedo ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Mast Cell ◽  
Growth Factor ◽  
Prognostic Marker ◽  
Vascular Endothelial ◽  
Immunohistochemical Expression ◽  
Mast Cell Tumors ◽  
Endothelial Growth Factor
Sign in / Sign up

Export Citation Format

Share Document